PARP1 and COVID-19: Moreover, given the mono-ADP-ribosyl hydrolase activity exerted by SARS-CoV-2, the utility of PARP inhibition (and its timing with respect to early vs. advanced infection) in the treatment of COVID-19 remains to be determined, given the delicate balance between efficacious vs. overzealous immune activation and the multifaceted role of PARP enzymes in this context.